These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 27622543)

  • 1. l-3,4-Dihydroxyphenylalanine induces ptosis through a GPR143-independent mechanism in mice.
    Ueda S; Masukawa D; Koga M; Goshima Y
    J Pharmacol Sci; 2016 Sep; 132(1):109-112. PubMed ID: 27622543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-DOPA sensitizes vasomotor tone by modulating the vascular alpha1-adrenergic receptor.
    Masukawa D; Koga M; Sezaki A; Nakao Y; Kamikubo Y; Hashimoto T; Okuyama-Oki Y; Aladeokin AC; Nakamura F; Yokoyama U; Wakui H; Ichinose H; Sakurai T; Umemura S; Tamura K; Ishikawa Y; Goshima Y
    JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coupling between GPR143 and dopamine D2 receptor is required for selective potentiation of dopamine D2 receptor function by L-3,4-dihydroxyphenylalanine in the dorsal striatum.
    Masukawa D; Kitamura S; Tajika R; Uchimura H; Arai M; Takada Y; Arisawa T; Otaki M; Kanai K; Kobayashi K; Miyazaki T; Goshima Y
    J Neurochem; 2023 Apr; 165(2):177-195. PubMed ID: 36807226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-DOPA-Induced Neurogenesis in the Hippocampus Is Mediated Through GPR143, a Distinct Mechanism of Dopamine.
    Kasahara Y; Masukawa D; Kobayashi K; Yamasaki M; Watanabe M; Goshima Y
    Stem Cells; 2022 Mar; 40(2):215-226. PubMed ID: 35257172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic associations of single nucleotide polymorphisms in the l-DOPA receptor (GPR143) gene with severity of nicotine dependence in Japanese individuals, and attenuation of nicotine reinforcement in Gpr143 gene-deficient mice.
    Masukawa D; Nishizawa D; Kanai K; Kitamura S; Kasahara Y; Hashimoto T; Takahagi R; Hasegawa J; Nakayama K; Sato N; Tanioka F; Sugimura H; Ikeda K; Goshima Y
    J Pharmacol Sci; 2020 Oct; 144(2):89-93. PubMed ID: 32763057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of Haloperidol-Induced Catalepsy by GPR143, an L-Dopa Receptor, in Striatal Cholinergic Interneurons.
    Arai M; Suzuki E; Kitamura S; Otaki M; Kanai K; Yamasaki M; Watanabe M; Kambe Y; Murata K; Takada Y; Arisawa T; Kobayashi K; Tajika R; Miyazaki T; Yamaguchi M; Lazarus M; Hayashi Y; Itohara S; de Kerchove d'Exaerde A; Nawa H; Kim R; Bito H; Momiyama T; Masukawa D; Goshima Y
    J Neurosci; 2024 Mar; 44(11):. PubMed ID: 38286627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoreactivity of a G protein-coupled l-DOPA receptor GPR143, in Lewy bodies.
    Goshima Y; Watanabe S; Seki E; Koga M; Masukawa D; Nakamura F; Komori T; Arai N
    Neurosci Res; 2019 Nov; 148():49-53. PubMed ID: 30590075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of the gene product of ocular albinism 1 (GPR143/OA1) but not its mutant forms inhibits neurite outgrowth in PC12 cells.
    Masukawa D; Yamada K; Goshima Y
    J Pharmacol Sci; 2019 Sep; 141(1):41-48. PubMed ID: 31606330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of ocular albinism 1 (OA1), 3, 4- dihydroxy- L-phenylalanine (DOPA) receptor, in both neuronal and non-neuronal organs.
    Fukuda N; Naito S; Masukawa D; Kaneda M; Miyamoto H; Abe T; Yamashita Y; Endo I; Nakamura F; Goshima Y
    Brain Res; 2015 Mar; 1602():62-74. PubMed ID: 25601010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of the L-DOPA receptor GPR143 in acute and chronic actions of methylphenidate.
    Uchimura H; Kanai K; Arai M; Inoue M; Hishimoto A; Masukawa D; Goshima Y
    J Pharmacol Sci; 2023 Jul; 152(3):178-181. PubMed ID: 37257945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson's Disease.
    Goshima Y; Masukawa D; Kasahara Y; Hashimoto T; Aladeokin AC
    Front Pharmacol; 2019; 10():1119. PubMed ID: 31632270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo antagonism of the behavioral responses to L-3-,4-dihydroxyphenylalanine by L-3-,4-dihydroxyphenylalanine cyclohexyl ester in conscious rats.
    Matsushita N; Misu Y; Goshima Y
    Eur J Pharmacol; 2009 Mar; 605(1-3):109-13. PubMed ID: 19168057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
    Alachkar A; Brotchie JM; Jones OT
    Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-DOPA Receptor GPR143 Functionally Couples with Adrenergic α
    Masukawa D; Takahagi R; Nakao Y; Goshima Y
    Biol Pharm Bull; 2023; 46(7):869-873. PubMed ID: 37394637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration.
    Lee WY; Lee EA; Jeon MY; Kang HY; Park YG
    Exp Neurol; 2006 Jan; 197(1):215-24. PubMed ID: 16269145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-3,4-dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase.
    Shimamura M; Shimizu M; Yagami T; Funabashi T; Kimura F; Kuroiwa Y; Misu Y; Goshima Y
    Neuropharmacology; 2006 Jun; 50(8):909-16. PubMed ID: 16504219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of Parkinson's disease.
    Camargo SM; Vuille-dit-Bille RN; Mariotta L; Ramadan T; Huggel K; Singer D; Götze O; Verrey F
    J Pharmacol Exp Ther; 2014 Oct; 351(1):114-23. PubMed ID: 25073474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
    Urs NM; Bido S; Peterson SM; Daigle TL; Bass CE; Gainetdinov RR; Bezard E; Caron MG
    Proc Natl Acad Sci U S A; 2015 May; 112(19):E2517-26. PubMed ID: 25918399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy.
    Chartoff EH; Szczypka MS; Palmiter RD; Dorsa DM
    Brain Res; 2004 Oct; 1022(1-2):71-80. PubMed ID: 15353215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.